Latest / Powering the Future Within / Episode 23: "Designing for Peace of Mind": Why Men Avoid Treating BPH & How Zenflow Is Changing That
Transcript
- speaker-0: Welcome to Powering the Future Within, the podcast where we explore the breakthroughs shaping the future of healthcare. I'm Omari Bachnight, CEO of ResidentLake Medical. Each episode, we speak with a leader who is driving the next wave of medical innovation, advancing technologies that are smarter, less invasive, and more connected than ever before. This is where the future of health takes shape. Let's dive in. Today, I'm excited to be joined by Shreya Meita, co founder and CEO of Zenflow. It's a company bringing a new approach to treating benign prostatic hyperplasia, better known as an enlarged prostate. Shreya brings a particularly interesting perspective to medical innovation. She's a biomedical engineer, a former FDA lead reviewer, and a Stanford Biodesign alum. Her journey has taken her from evaluating medical technologies to building a company and bringing its own technology to patients. ZenFlow's Springs System received FDA approval in December 2025. And the company just recently announced a $52 million Series D financing and an exclusive U.S. distribution partnership with Cook Medical. It's an exciting moment to hear the story behind those milestones. Today, We'll explore how Shreya identified an unmet clinical need, the persistence required to turn that insight into a product, and what she's learned about leading a company from development into commercialization. Shreya, welcome to Powering the Future Within. I'm really excited to have you on. speaker-1: Thanks, Amari. I'm excited to be here. speaker-0: So it was really interesting to see that early in your career you were exposed to UPMC's really ambitious artificial heart program. It's a a program that's really close to my own heart. So I'm curious, what was your role in that and and what was it like to begin your career in an environment where engineers and clinicians were attempting to replace one of the body's most essential organs? speaker-1: So that was that was my introduction to MedDevice, you know, and it was a really important and insightful one. so that the artificial heart program, for those who might not be aware, it was when I was in my master's program at Pitt and UPMC has essentially a program where you sign up to be a technician for intraerctic balloon pumps and artificial hearts. And It was my first foray into really seeing a medical device at work in the hospital. and that was just, you know, I had I had been on the other engineering side of things, manufacturing side of things, on the business side of things, but not really seeing it touch patients' lives so intimately. And I learned so much from that experience. I learned what it actually means to have a product in the physician's hands to watch them use it. And then the thing that I thought was most insightful about artificial hearts and and you know intraartic balloon pumps and VADs in particular is that they were these are truly life saving devices. They were feats of engineering and at the same time, VADS were considered a bridge to transplant, which was, you know, the step before a heart transplant, taking your heart out and putting another one in. And one thing I learned while understanding that as part of these clinical trials that were ongoing at UPMC was that engineering has its limitations and the body's own functions are so unique and complex. And we should always be considering that as we consider, you know, how we develop these types of products. speaker-0: Was was Dr. Cormos still there while you while you were there? speaker-1: He was, yeah. He was there. And it was just such a it was so in I didn't realize what I was getting into. They say youth is lost on the young, right? speaker-0: Ha ha. speaker-1: Realized. now of course in hindsight, the luminaries that I was surrounded with and who I got to learn from and it was it was genuinely a joy. And then you know, that transition going from there to FDA was really interesting because I ended up being a lead reviewer on on ventricular assist devices in particular and girl in heart, which was the pediatric VAD, that was approved. So I was the lead reviewer for that. So it was wonderful to see the clinical side of things and then being on the regulatory side of approval for those products. speaker-0: Well, I'm and I'm curious because I mean you're you're at UPMC, which at that time and still is one of the the leading institutions focusing on these very complex technical devices, artificial hearts and LVEDs, as you say. And then you decide to go to the FDA. So what was the what was kind of the driving thinking behind that? speaker-1: Was funny, Omari, is I didn't think I would ever be interested in working for the FTA and I definitely thought that it was just a paperwork exercise and I didn't wanna get, you know, drowned in the bureaucracy of working for the government. What changed my mind was actually meeting somebody who worked at FDA and in particular at the time they were trying to understand the functions of the heart and with medical devices that were being developed for the heart, how might we consider what they call in silico testing? So I was also working on my master's for, you know, some computational fluid dynamics and finite element analysis of heart valves. And it was a question of how do we utilize these types of, you know, computational programs potentially to replace, let's say, animal testing that companies do to qualify valves, for example. And so that I I came to understand a little bit more about the technical expertise really required inside the walls of FTA and how that played a role in the process of approving medical technology, which I just didn't I hadn't had that vantage point before. And so when I learned that it wasn't just a paperwork exercise, that it was more scientific and technical, that piqued my intellectual interest, obviously. And then there was an element of I love the idea of understanding. the regulatory process, sitting on that side of the table and if one day I want to develop my own device, let's say, hypothetically, then I I know what it might be like to go through that process. So I from a career perspective, it felt like the right move and I'm still so grateful to have made that decision. One of the best in my career, I think. speaker-0: Yeah. So I'm really curious. I mean, when you talk about something like computational fluid dynamics, you're thinking about blood flow, for example, a biologic flowing and coming in contact with an artificial interface, you know, like a titanium, for example, with the responses, its ability to not clot, not cause things like thrombus. And as you say, one of the areas that's always been explored is can we come up with these models that are predictive? And perhaps replace a portion of either animal study, animal evaluation, or some portion of human trials. Is that somewhere you think we'll eventually get to with artificial intelligence and our ability to apply some of these techniques like computational fluid dynamics that will be able to replace some of these more kind of boot force methods with animal testing, for example? speaker-1: could get really close. I don't think we're there yet. There's been a lot of development, even on FDA side. And like, you know, kudos to them for making a lot of progress there and thinking critically about what companies need to offer to, you know, de-risk some of the the safety risks. at the end of the day, you know, I kind of started with this with the artificial heart program is your your body's biology is so unique and it's hard to replicate an engineer. And there's a wide range of anatomies out there. There's a wide range of, you know, compliances of tissue depending on what disease you have or how your cells are. and and so it it can be the solution set to different tissues is so broad that I think that it becomes challenging to think about, you know, being able to mimic that in a way that puts a majority or most of the risk to to bed before going into humans. but I do think we're getting closer. I definitely think we're getting closer. And now with the layer of AI, hopefully we can get to a point where, you know, I'm I'm vegetarian, so I love the idea of not testing on animals. I like animals. and and I think there's probably better ways to reduce risk. but that still remains a gold standard for anyone who's interfaced with FDA recently or, you know, gone through an IDE process. Usually, especially with like a permanent implant, you are talking about animal studies and it's hard to back out of that for now. speaker-0: Right, right. No, absolutely. But it's exciting to see where we're going and and maybe we can even reduce the number, you know, the ends, that kind of a thing in terms of the the number of study participants or animal participants. And speaker-1: Definitely. speaker-0: and so you go then from from FDA and you join the Stanford Biodesign Innovation Fellowship. And Stanford Biodesign is so interesting. Every time I talk to someone who participated in that program I don't know what they put in the water there, but it seems as though people really buy into the thesis, the theories, the concepts, the approaches and come out really, really energized. So I'm so curious at what your experience was like. And for those maybe who've heard of the program but don't really know some of the details, just give some perspective around the fellowship. And it's considered to be kind of a needs driven approach, which is an approach I know you buy into. I'd love to hear a little bit about your perspective on that. speaker-1: Absolutely. I mean, I I applied to biodesign partly because I wanted to come out to California. I was born in California, loved California. I was in DC obviously and wanted to come back. but also, you know, I had a very I'll say an educational drive to understand holistically the different facets of of med device innovation. And, you know, I'd never crossed paths with anyone who'd worked through a reimbursement issue, for example, or thought about fundraising. And so I took a very educational approach and applied to that, thankfully got in. I think the thing about biodesign, and you're right, I've drank the Kool-Aid for sure. because it just made logical sense to me when the philosophy is a needs pull rather than a technology push. And as an engineer, you get caught up in the excitement of the engineering of the thing. And you wanna kinda push that into a space when you're a hammer, you're looking for nails, as they say. And and I think the unique thing about the biodesign process is you're always centered around what the need truly is and what that translates to, especially now that we're entering into this commercial phase that Zenflow is listen to the voice of customer. That's essentially what the philosophy embodies and it results in a better product. it results in a product where you're actually taking all of that into consideration instead of trying to just shoehorn ultrasound to a new indication, for example. Right. So it's it's a really it's a really holistic approach and one that taught me a lot about about the field. speaker-0: Right. And so Zen Flow emerges from the biodesign experience. So so how did you kind of come across BPH, benign prostate hyperplasia as a clinical unmet need? I'm just so curious on how that became the problem that you were willing to spend the next decade trying to solve. speaker-1: To be clear, I didn't think it would be a decade. Naive enough to think that we could do it faster. but yeah, you know, the biodesign process, the way that they execute on the fellowship program is that they partner with Stanford Hospital and particular departments at the Stanford Hospital. Every year they choose a new specialty or two. And the year that we can we were in the program was 2013. and that year was urology and nephrology. So the amazing thing about that program is you have the ability to firsthand sit next to the physicians and shadow them. And you know, you could go into their private clinics, you go into the operating room. And the idea there is that you get first hand experience of the pain points of all the stakeholders. And it's it's a great way of understanding the unmet need because oftentimes when you hear people and what they want, that could be different than actually what they need. And one thing that I noticed right away was that as men were talking to urologists about their symptoms with BPH, there's fear in their eyes. And sometimes I half jokingly kind of talk about the fact obviously a female led company over here. I, you know, don't have a prostate, but I've been to the Obigaine since I was in my teenage years. I, you know, we have monthly menstrual cycles, we have annual pap smears. Some of us have the privilege of of giving vaginal birth, right? We're sort of women in in sharp contrast have, you know, been poked and prodded there down there their entire lives. And I think for men, it's really not until BPH or maybe a vasectomy comes around that they're contending with something that's not, you know, relief or pleasure. And what that means is when they're faced with BPH and they're talking to their urologists, they are scared. Of what that looks like. What does a procedure look like? How much pain am I going to feel? Really, I need a catheter. I'm only 45, right? Men at that age are physically active, they're sexually active, and they were shying away from the current solutions because they were so invasive and painful and had all these, even just short-term things. And the reason why I think the biodesign philosophy led us down this path is because we truly listened to the patients. And if you talk to a urologist about unmet BPH need at that time. I've heard things like, it doesn't matter if we use a rigid scope. People place cat we place catheters every day. It's it's not a big deal. yeah, men get a little bit of bleeding. They'll get over it. And and what we really saw was, okay, if this is an elective procedure, if we want to move the market, if we want to inspire patients to do something when they wouldn't have otherwise, it needs to truly be patient friendly. And Yeah, that's why that's why I've drank the Kool Aid because that's the true unmet need is listening to the patient. speaker-0: Right. Well, I mean, but there's so many things that are interesting here. For one, y you were obviously trained as an engineer. You started your work in a very technical field on artificial hearts. And then you move to the FDA. Both of those sort of fields, if you're just to think about typical engineer and if you're sort of to think about a typical regulator, aren't necessarily living every day near ground truth. That is the patient experience. And I certainly appreciate that the the biodesign program. Helps to support the philosophy of getting to ground truth, user needs, clinical needs, patient needs. But it still takes a person that has that level of empathy to do what you did, which is to say, see the fear in a patient's eyes. That's not something that a typical engineer would express, certainly not something that you would necessarily hear coming from a regulatory domain like the FDA. And even with the biodesign philosophy. Yes, you can help support the process, but it takes a person to be able to see that through. So I'm curious about your own experiences. Is there something there that you think helped you to to kind of see that, feel that, understand, look, this is a there's a need here that maybe even the clinicians are not seeing, something that they need that's unspoken. speaker-1: Yeah, I don't know. I mean, I it just seeing it in their eyes and the actions that they took. I do have a a personal experience with BPH. My my dad had BPH, and my mom told me about it. He would never see wasn't ready to admit it. But that in itself tells you something, right? This is a really intimate problem. And even the solution, what you decide to elect to undergo is an intimate decision. And so that's it's just a very It's a very personal thing. And and sometimes we can be, you know, there's definitely huge unmet needs in women's health. there's also unmet needs in men's health, and those problems are important, that fear is real. And I think that there's a little bit of a a lot of my approach in any stage of the company has been a a very problem solving one. So we know there's sixteen million men who have BPH each year. That's an that's a incidence number. And it is there's a reason why only two to three percent elect to undergo anything. And so it it's not just a matter, there's of course the empathy component of how do I unlock that big market that I know is there. Right. but it but it's also a it's a real numbers thing. And it's it's as I go out there and pitch, I can share that story really confidently of there are all these men that want something. It's an elective procedure. We may better make it something that's actually palatable to them. speaker-0: Right. Absolutely. So you go about that process trying to understand how do I kind of fill that gap? How do I make it palatable for them? And of course, like every every great entrepreneur, you turn to the garage for your earliest prototypes, right? I'm I'm curious, what were you trying to solve for in in those early prototypes that has kind of followed all the way through to the current design of the Spring system? speaker-1: That's that's a great question. So a lot of the reason why the solutions that were there and are currently out there weren't as patient friendly is because there were some technical issues with making it patient friendly. So one thing in particular is we have a flexible scope. makes a huge difference to patient comfort, but that is very technically challenging to achieve deployment of an implant through a flexible system through a tortuous path. And so those early days in the garage were partly, you know, how do we get an implant where we want it through a flexible system? and then the other challenge that we were faced with was our our implant is somewhat stent-like in shape. And stents failed in BPH in the past. And so we were also contending with how do we avoid those failures? How we how do we design it such that we're not facing those failures. And the implant design that you see today was the hard work of many, many, many, many hours and days in that garage of iterating on the design. and now I have like a library of images that I've kept just I didn't realize how important they were to keep in hindsight. But but in hindsight looking at them, I'm like, okay, there was a process by which we evolved this by learning and iterating. And so part of it was obviously a technical challenge of how do we deploy this in a way that's truly patient friendly? And then part of it was putting to bed the risks that these types of devices have have you know manifested in in the past. speaker-0: Yeah. No, it's really interesting. This this challenge is one that applies to a lot of anatomical domains. We spoke to the CEO of Jupiter and he talks about how difficult it is to deliver something requires rigidity of the catheter, but the at the same time have the flexibility to kind of go through the tortuous anatomy without causing issues as you go through. And it sounds like you were solving for something very similar in this in this condition. speaker-1: Yeah. We're all we're all trying to put big things in small holes. speaker-0: Yeah. speaker-1: It tends to be the medtek mantra. speaker-0: I'm picturing the the the tagline. speaker-1: Yeah. We we go with a little bit of humor and urology. It's it's okay. speaker-0: I love it. I love it. So not surprisingly, you you've championed putting engineers directly into the clinical environment in front of physicians, in front of patients, rather than just focusing on physician interviews and market research. Have there been some assumptions that your engineers have come back and really said, look, we've got a new insight or understanding having stood in the clinical environment rather than just kind of being at arm's length? speaker-1: Definitely. Definitely. And I that's something that I continue to encourage. The engineers want they should be in the field. Oftentimes they want to be in the field seeing the devices at work. Because the process of observation through biodesign was so powerful for me, I carry that with me still. And what it led to was a better product, hands down. And what that means is I wanna see the people who are actually doing the design work to experience that firsthand. So a good example would be You know, we have a number of steps as part of our procedure. And I was doing a number of I think I proctored something like eighty percent of the pivotal trial cases speaker-0: Is that right? speaker-1: when I was CTO. mostly just 'cause we wanted to really have our arms around it and and and you know understand what was happening in the field. and one thing I would come back with was like so a lot of steps and I would mention a small thing. Let's we have a stockcock on our system, like yeah. One of the things I see that they mess up on the most and it's it's actually surprising. It's just a stop cuck. It sounds simple. And if you're an engineer sitting at your desk, catting up the next thing, that's not something that you think is hugely impactful. Right. but the engineers who went in the field, the ones who watch them fumble with it, who watch them not bring the balloon completely down, or even watch them drop it on the floor and now you got a non-sterile product, you gotta go open on that one. These things, actually witnessing them play out. was so much more impactful to them understanding why it was important, even though if you're just sitting at your desk, it doesn't sound like it would be. And so we've we were able to, we, you know, we had a someone leading up what we call therapy development, which was, you know, g a pro a a proctor out in the field coming, bringing back notes and sharing it with the RD team on a weekly basis. And we even started tallying certain, you know, metrics and how how long and how, you know, how difficult and how many people and And then we and then we really zeroed in on, you know, the next gen device and what we think will be impactful for that. So none of that should be somebody sitting at a desk and just dreaming up what they think is is good. it should really be based in what's happening in the field, real time feedback. We also want to be keep our ears open of what people are complaining about, what's not ideal, what they would like to see. and then also obviously first hand observation is just is probably the most powerful. speaker-0: Yeah, it's amazing how much workflow really matters. And when you're working through workflow or process on a spreadsheet or through a piece of paper or through a, you know, kind of workflow diagram, it's really easy to kind of hand wave and say, you know what, that's really not a big deal. You know, having to deal with the stopcock really is not a big deal. And then you say, No, go out into the field and see what our physicians or surgeons are dealing with. And they they you see the surgeon kind of turn around and give you that little look. You know, as a as a political engineer and you gotta go, Yeah, okay, I get it. I Yeah. And and workflow matters so, so much. But I I'm also just really curious. So if you were doing if you did eighty percent of the proctoring during the pivotal trial, you know, having proctored a bunch of cases myself in other fields, there are always aspects of the way that you kind of help try to run a room that are subjective. And are not necessarily objective. Did you find that you needed to find ways to take some of the subjectivity, you know, little coaching, you know, okay, counterclock here versus not, those types of things that you might just kind of know innately and needed to find ways to make them objective or make them standards as you went from, you know, proctoring eighty percent of the cases to now obviously you proctor zero. speaker-1: Yes. yes. And I'm actually still learning that lesson. And you know, when I recently, so we have a a director of training and we were out in the field recently and and you know, he was observing a rep that was helping get us through the case. I was just there relationship building, saying hello to the doc and then our director of trainings taking notes. And there were certain things after a a training session with that new doc, and I was like, you know. You should ask them to do this. Here's what I found really effective during the trial. They should put their hand once they do this, I've seen this a lot. And then when they do this, they're much more comfortable. And all of a sudden we're putting all this pen to paper on, you know, internal institutionalized knowledge that you then have to scale. And the goal in the dream is that I'm my my dream I often say is I don't know when cases are happening. Right. And what I mean by that is this is bigger than me. It always was and it will be. And and so we need to sort of protocolize these things that live in my brain or might live in some of the engineers' brains, that make just make it a better product. And we wanna continue to feel mission driven in making superior products for our patients. Yeah. speaker-0: Absolutely. Absolutely. And I'm also just really curious, having been at FDA and then, you know, buildings inflow from from concept all the way to product, all of a sudden you're on the other side of the table from where you were. Were there things that maybe you took for granted or didn't really know until you were on the sponsor side of the table versus when you're working at FDA? speaker-1: Definitely. Absolutely. And that's just natural, right? We only we only bring the perspective that we're from the seat that we're in. And I think being on the other side of the table definitely had more of an appreciation for the struggles that sponsors have, capital limitations, time limitations, timeline, you know, commitment to the board and and bigger picture things. I also think it's important that we have a lot of empathy for the people who are sitting on that side of the table. And that's something that I brought to our team because I had that experience. So I'm like, we're guys, we're not the only submission on her desk right now. She's got five other five ten Ks, three IDEs and probably a PMA, you know? And so let's just keep that perspective. And here's how we can balance that while also pushing our our plans and objectives forward and how we communicate is important. When we do it is important. And and I think it's it's important perspective to have to build that relationship. One thing I often say is for some reason people have sort of a mental block with the government and and building relationships with government entities, the reality is it's another business relationship that you need to foster and maintain. And you have to appreciate what they bring to the table and what you bring to the table. And you know, if you're negotiating with a supply vendor, you know, one of your vendors, for example, you're not gonna expect them to give you product for nothing. They need to make an income. They need to have, you know, they need to make money off of the components that they source to build your subassembly. And you know that innately as a business person. You also have to bring that perspective to a regulatory body. Here's what they're trying to protect against. And I think it's really important to keep that in mind as you have your conversations. It's really important to challenge their assumptions. Of course, you're gonna have a push and pull, that's natural, but bring to the table with an understanding of the perspective that they bring, because that's going to be much more you know, persuasive and it's going to be much more impactful to take that approach. speaker-0: Right. Right. And so okay, now you you've got an approved product, as you mentioned, sixteen million, I believe, in the US alone with BPH, but you only have what, maybe forty thousand that are are getting a a more advanced treatment option. So what are you what are you doing now to get others to consider, you know, patients and physicians to consider an implant? you know, given the gap between treatment and and opportunity. speaker-1: Yeah, well one of the things that's really critical about our system is that the Zenflow spring implant is completely removable, making the procedure completely reversible. Now there's two things that that does for us. One of them is it provides a peace of mind for the patient. Again, that fear in their eyes and and providing them a solution that will will help reduce that anxiety of if anything ever goes wrong, you can take it out. And and nothing's, you know, there's there's nothing lost in doing that. so there the reason I bring that up is because it's a really important component of the new category of therapy that we're creating, which we call first line therapy. So because it's done with a flexible scope, it can be done in an office-based procedure, no post-procedure catheter, no bleeding. That means that it can be done, you know, in a way that's that's much less invasive than anything else out there. So The removability becomes important because that's a peace of mind for the patient. And it's definitely a matter of convincing the patient that they should do something rather than nothing. So when we talk about the gap between the 16 million and it's about 400,000 men who are currently getting either a more invasive or a minimally invasive surgery, it's putting that ease into their mind of this is going to be a much better experience. You can bail if you need to. and your options still remain open. The reason why first line therapy is important is because there's about eight million men who start drugs every year, either an alpha block or a five ARI or some combination thereof. And they end up either with really poor results. and just so you know, the effectiveness of these drugs is about on level with the placebo of our of our clinical trial. So it's really poor effectiveness. Most men, about half of men 12 months in stop their drug therapy. So they stop taking it. It also comes with terrible side effects, including sexual dysfunction. And you talk to any man about sexual dysfunction, it's the last thing that they want to see. it's really, really natural, of course. Like it's really important to them. And and so with those side effects of the drugs, and when we provide a therapy that's flexible, doesn't require catheter, allows you to bail later on if you need it. All those things combined mean that we have access to a larger swath of patients than anyone has ever had before. And so how do we get them to elect to undergo a procedure? Make it patient friendly at the risk of being, you know, overly simplistic. I think all those things really matter. speaker-0: Right, absolutely. And so what did what did you find through your pivotal trial? What did that data look like? speaker-1: Yeah. some great data. We see really great effectiveness results. So men who underwent the spring therapy had, you know, seventy-one percent of men reported satisfaction with their improved results. most men who suffer from BPH see, you know, frequency, urgency, a sensation of not completely emptying the bladder. And we saw really great results on effectiveness across the board. it's more or less on par. With some of the other minimally invasive technologies like EuroLyft or Resume. so that was really great to see, to see that effectiveness level. I would say the thing that's most outstanding and the thing that we've been talking about this whole time of how do we bridge that gap, the safety outcomes are exceptional. So as opposed to anywhere between 50 and 80 percent procedure device related adverse events with other therapies, we're at 12% at 12 months. And so it's dramatically lower. What that means for the patient is the most important. They're not seeing as much bleeding, they're not seeing as much pain on urination or any of these other side effects that they would suffer from with those other therapies. So again, it kind of comes back down to that unmet patient need and what's going to be best for them. those results just further underscore the benefit of our approach. speaker-0: And so in terms of the clinical evidence that supported the approval, it sounds like part of the consideration were patient reporting outcomes PRO, which is something that FDA has kind of leaned into quite a bit with evaluating some of these types of devices. Was it primarily PRO driven or was that just part of the part of the evidence package? speaker-1: That's right. It's the main score that you use for BPH is the International Prostate Symptom Score. So that is a patient reported outcome. It's it's a it's a subjective measure. So the primary effectiveness endpoint was related to the patient's IPSS improvement. So yeah, that's that's what they used to make that determination. And the threshold for FDA was, you know, a comparison at three months a comparison against the placebo or sham arm. And then at twelve months a comparison of their IPS score from baseline to twelve month follow up. So yeah, we we met the marks on on those and and I think it's really powerful data for a patient to see how their effectiveness can be or you know, their symptoms can be improved with those effectiveness. Yeah. speaker-0: Yeah, it's great to see the PRO data being considered in in these studies and and I think in your design having a placebo or sham arm is really helpful because then it really allows you to show that the patient reported outcomes is a is a real, you know, phenomenon. and it's not just something that is driven by a placebo effect. So having that placebo or sham arm I think is incredibly powerful and and I I assume something that allowed the FDA to really say, Hey, look, we're willing to support PRO being being a major driver of your evidence package here. speaker-1: That's right. And I I think it's it we would be remiss not to note that PROs are also they can be a little fickle. You know, when you talk about the range of outcomes, you can have patients, we had patients in our sham arm who definitely thought they got the therapy and who definitely reported an improvement at three months in spite of not receiving the device. and then and then there's the opposite. We saw patients that had really great, nice opening implant was in there and they were convinced they got the sham because they don't feel better. so the power the mind is very strong. And and so sham control studies can be can be challenging to prove a a difference because you see such a wide range of outcomes. But of course, the proof is in the pudding. When you get down to the majority of patients and what they experienced, that's all that's all positive and that's how we win an endpoint. but you know, it's it's with these PROs, it it is it can be a little bit tricky to execute a powered study. Yeah. speaker-0: Yeah, so I'm curious because when you when you think about fundraising, and we'll talk about some of your more recent news here shortly, but when we talk about fundraising from an investor's perspective, they obviously want to minimize risk. And so you were looking at embarking upon a major sham control pivotal trial. What what was the evidence you needed before that, maybe in early feasibility studies? to give you confidence to go into a sham controlled study. And then I'm also just kind of curious what did the sham arm look like from a procedural perspective? speaker-1: Yeah. so I'll tackle the first one first. The the thing about IPSS and BPH is that's the gold standard. So there was a little bit like we don't really have a choice. Now the risk is of course just as exactly as you define, which is that there is because it's a patient reported outcome, it's a little bit harder to meet endpoints or be certain that you're going to meet endpoints. The approach that we took and our board was very adamant about. is we want to have as much confidence as we can before we go into the pivotal study. And one thing that differentiates ZenFlow from other competitors out there is we treated a hundred patients prior to our pivotal in pilot studies. And we actually learned a lot in that process. And so the board was, you know, by the time we got to the a place where we were ready to submit the IDE, the board felt confident that we were going to meet those endpoints and that the long-term outcomes of that study were going to be durable. And you know, the thing about entering into a pivotal study is you're going to live with those outcomes for a very long time. it's not, you know, there's the immediate need of FTA approval, of course. but the pivotal study isn't is a paper that everybody holds, everyone's watching, two year data, five year data for a permanent implant. That's just that's the nature of the beast. And so we wanted to be sure that we conducted enough studies prior to the pivotal to feel confident in that evidence base. And So we we conducted several studies prior to the pivotal. There was learnings throughout the throughout the journey. We developed additional sizes, for example. We've now found that that's really critical to our patients. Some patients, again, nobody's a monolith. There's always a range of patients. They're different sizes, they're different diameters. And so we now have several sizes that we incorporated into the pivotal. It's great to have that. It does take more time. and capital to build that evidence base, but now I'm so grateful that we have that. And then now we have really great pivotal data and we just continue to build upon it. your question about the sham, it's so the sham was just a a a catheter that was inserted into the patient. the balloon is inflated into the bladder and and then we there was a noise maker that FTA required us because many of these patients were awake. about half of our patients in the pivotal trial were under local anesthesia. So we had a sound a a noisemaker that sounded like the deployment of the device. and and so that was, you know, that that's how sham studies go. You just you you just have to sort of do what you can to make it seem like they're undergoing the procedure. But yeah, it was it's an interesting process to execute that study. speaker-0: Yeah, but it definitely ends allows you to generate really powerful data on the other end and then, you know, most of the time I'm sure it's the same for you. You have a crossover for that patient population to be able to get the the device if they want to after a certain period of time. speaker-1: Yeah, that's right. And you know this, but I I think it's worth, you know, repeating is just that building an evidence base is the most valuable thing you could do for any product. And, you know, having the perspective of having been at FDA, you know, when I was in biodesign and we're talking about regulatory paths for different types of solutions. And as innovators are kind of in that early stage of figuring out where they're going to land with a regulatory path. I now advise some of the biodesign teams. And one thing that I share with them is that just because you get, let's say, five, ten K clearance, you know, two years before you amass clinical data doesn't mean you're gonna hit the ground running on sales. Absolutely. The evidence base has to be there. And so to some extent, I I I don't want to say it didn't matter if we were a class two or a class three. It did, it does. but The real reel is making sure that you have the evidence that you need to hit the ground running in sales. And that's when the real inflection point comes into play. And so it's just a side note that, you know, regulatory path is important, but building your evidence base to actually be clinically meaningful from a marketing standpoint is is the is that's gonna be the difference between, you know, commercial success and that. speaker-0: It it's such an important point for multiple reasons. One of which I think is really interesting is that if you're attracting investors that understand that this is need going to need to go through pivotal with all the evidence generation along with it, it's going to be a different investor set than if your pitch is saying, look, I think I can get by with a 510K and a de novo. Great, but approval is just the start. And if you don't have the clinical evidence plus, plus, plus, plus, plus, you don't stand a chance and now all of a sudden You're sitting with an investor group that looks a lot different than if they know it's a class three up front with a pivotal study coming. speaker-1: Yeah, exactly. And and from that perspective, I'm just so grateful for and I I mean that, this is not just lip service. Like I am very grateful for the board and the investors that we have around the table because they're sophisticated enough to understand that that investment into the early clinical data, into that development process into really nailing it before we get in the pivot pivotal was critical dollars that went into the company that will now drive our our commercial success. speaker-0: Well well kudos to you and the team and the board for making that investment. And you know, what it's all led to is the exciting news that just came out about you closing your Series D. Congratulations. speaker-1: Thank you. speaker-0: Securing distribution with Cook. So what what's the backstory there? speaker-1: Yeah, so so gosh, where do I start? I mean, you know, fundraising is always hard. It just it just is. And today's environment I think is especially challenging. I'm super proud to have closed this round. N it's never easy. so we entered into the series C financing with Cook at the table, which was super exciting. Cook was clearly interested in the BPH space. They also made it clear that they wanted to, you know, entertain the conversation about distribution agreement once we achieved PMA approval. So we kicked that off once we got approval in hand. Cook is a fantastic company. And one thing that I realized in the process of, you know, working alongside them, having a board member on our board from the Cook team and seeing how their company's growing and shifting. I was just really inspired by their approach. And I think that they they know and we are fully aligned on the potential to grow this market into first line therapy. And so there was so much between our teams that we aligned on that philosophically we agreed on that make Cook a really great partner for us. and as you can imagine, because it is a tough fundraising environment, there's also this perspective that myself and the board brought, which is, you know, I can go out and raise 80 million, $90 million round. We could all get We all get diluted in the process. We all know how that works. Or we can, you know, and build that on our own. Or we can partner with a strategic who wants to be in it, who's committed to doing it really, really well. and that's a much more capital efficient path for us to demonstrate real commercial traction, excitement, all the things that you have to do in these early launch days. And and like I said, there's, you know. the the cook partnership is is real. It's it's very it's very deep and it's meaningful. distribution agreement I've found doesn't quite give it the credit that it needs, which is that the fact that we're going to be meeting as a committee on a frequent basis. we have weekly meetings with them already on on thinking about strategy. And so the way that we're both companies are approaching this I think is genuinely unique. and I think is, you know, hopefully will be a blueprint. for companies like ours that need to get through this early commercial stage to really prove themselves and prove the appetite in the market while also doing it in a way because we're all cash strapped that is capital efficient that, you know, can help us really demonstrate that value without necessarily banking the bank. speaker-0: Yeah, no, it's a really smart approach. And at this stage and phase, distribution is so critical and important. But it I think you've also been really smart about how you still have evolved your organization to kind of match this partnership. Maybe you could just speak a little bit to how you're evolving your org. It's not as though you're just gonna make the product and throw it over the fence. but for someone who did 80% of the pivotal trial cases. In terms of proctoring, I'm sure you're not eager to just hand your baby over without appropriate engagement, right? speaker-1: Yes and no, right? The dream is for it to be way bigger than me. but yeah, I you know, for me it's it was really about having the right voices at the table and being aligned on how to do it well. And I think the the cook partnership has been just really insightful because we meet often, we talk about strategy. The cook team is so dedicated to doing a great job with this. We have you know, a training program that is not just about here are the steps of the procedure. Our training program is tell me about your BPH practice. What do you what do you use to treat right now? What are you hearing from your patients? And it's really truly a consultative sales approach. and and when I say we're philosophically aligned with Cook, they get that. They know it. they're building a a dedicated sales force to focus on this product. And And all of that is really like I said, it's unique and differentiated. And that's what made this partnership so compelling for me and the board. speaker-0: Yeah, amazing. And a lot of times, you know, you get that FDA approval, especially after pivotal trial, and you think to yourself, I made it and it's really just begun. So putting that in place has been so, so important. But also during this process, you've managed to navigate a very challenging reimbursement environment. Maybe you can just speak to that a little bit. speaker-1: Yeah. So we we created our own category three codes. as sometimes is the case with a space like this, there are existing codes that you could try to use to kind of shoehorn, you know, your way into in into existing codes. We found it most beneficial to to lay out the details of our procedure. It is a unique we're starting a new unique you know category of BPH therapy. And what that means is you know, not just implantation of the device. We also created a code where replacement is is an option. so we have three different sizes of implants. We've actually found some patients, they might can you know their prostate's continuing to grow. They might need a larger implant five or seven years down the road. We're actually able to do that. And so we want to make sure that there's a code associated with that procedure. And then of course an outright removal. I as I mentioned that's an important feature in first line therapy and a nice peace of mind for the patient. So there's a code associated with that as well. So we created three codes. That was well before FDA approval, but we wanted to put those codes out there, see if we could achieve them and then start working toward pricing them, getting the an APC level for those codes as soon as approval came through the door. So we did that. And in March of this year we were able to achieve an APC level six on the implantation and replacement codes, which is a really high payment level for twenty twenty seven that lands around eleven thousand dollars per procedure. that is incredible even for for BPH procedures and and something we're really proud to achieve. And as you can imagine, you know, changed the tenor of the excitement around ZenFlow, negotiation points. And and so we landed in a really, really favorable place, which I'm I'm thrilled about. And, you know, the the reality is sometimes we You know, we don't want to overstate the you know, the dollar value of of these procedures. This is important health care that we're providing to our patients. The reality is physicians want to be compensated for the time, their equipment, and and so we want to make sure that that's a fair shake and and feels really you know, valuable for the physician to to to to practice these procedures. So excited that we got there. There's still work to do. A category three code is is never easy to execute on. You know, we maintain all of the all the relationships with the AUA coding reimbursement committee, the society relationships are really important. The you know, how we operate under this category three code is really important. The case by case coverage that we need are the, you know, the case by case you know, prior to medical necessity letters, all of those things will require a lot of work. But at the end of the day, because the payment level is is high, we're really excited about offering that to our physicians. speaker-0: Wow. So you so you've truly worked through product position, price, placement, or distribution. So every single aspect of when you talk about an academic exercise of creating a business, you've done it. but you've said that you didn't initially think of yourself as an entrepreneur. So I'm curious because that that's more entrepreneurial than any entrepreneur essentially out there. Like it's basically the classic entrepreneur is what you've delivered on. So when did that self perception finally change and how would you describe yourself today? speaker-1: That's that's so funny. I yeah, I I did not consider myself an entrepreneur. I definitely consider my myself an entrepreneur now. Good. things yeah. The thing that I think I've realized, Omari, is that I am a problem solver. And I am very good at solving puzzles. and and what that means is when we're crafting strategy about how does this piece fit with that piece, that is something that is that is definitely a strength of mine. And when I didn't call myself an entrepreneur, I think I was dismissive of the value of that skill, you know, and and I think now now, of course, being an entrepreneur probably something I'll call myself my whole life. I I I see the value in that now and I and I I get it a little bit more. I do think you have to be mindful about, you know, I went from chief technology officer to CEO. And that the role change, my title change I should say, but the reality is that there's a certain phase of the company's life where R and D is in the spot like that is what's really important. You gotta figure out the next iteration, gotta get the product right, especially something as important as the implant. Everything from the implant to the stopcocks, right, is is important. And I'm glad that I was CTO at that phase of the company. And then and then you sort of try like you transition as a regulatory hurdles of the PMA. And getting through that and I put my FDA hat on at that phase. Now that we're into commercialization, what's really what I'm genuinely enjoying is the problem solving piece of this. It's like, okay, here's a reimbursement piece. Okay, I know that this is what we experienced in the pivotal trial. How do I adapt that to the mindset of a consultative sales role? Right. Like how do I consider that whole picture? How do I make sure that I feel good about how Cook's resources are trained for that? And so I don't know if I'm answering your question. Perhaps it's a long winded answer, but it it comes down to putting all the pieces together, problem solving. That's my strength. I don't I don't pride myself as being an expert in any given phase. but I do have a poster in my office that I'm looking at right now and it says everything is figure outable. Yeah. And I genuinely believe that. I think I think with the right people around the table, with you know, enough With enough will, there is a way. and and oftentimes we you know, we face challenges at at any startup we face challenges, but I think working through them is is is oftentimes a matter of strategy and grit and and we've been able to to get this far. So I'm pretty proud of that. speaker-0: Yeah. Well I'm curious after all this, artificial hearts in Pittsburgh, FDA in in DC, and then biodesign in Silicon Valley, and of course over a decade of buildings and flow and kind of going through this process of discovery both professionally and personally, could you envision yourself becoming sufficiently obsessed with a problem like this again where you would do it all over again? speaker-1: it's such a good question. it's a hard journey. I'll say that. It's a really tough journey. And one of the analogies I have, so I'm actually personally I'm a I'm a cyclist. I I ride my bike hundreds of miles sometimes. And there's a the reason I bring that up is because there is an analogy to the endurance that something like Zenflow takes. And there are times where you are pretty much certain you're not gonna make it. You know, and somehow you climb out of it and you and you make it anyway. that takes a toll, you know, it is it is taxing, it's tiring, and there's moments where you're like, Why am I doing this? and then you remember that you've got an amazing team, you've got an amazing product that's going to help patients and make a true impact, and you keep pushing through. Whether I do it again at some point, I think partly depends on who I might do it with. speaker-0: Right. speaker-1: the people really matters and how big of an impact I can have. you know, I'm I I'd like to believe I'm a a very humble person, but it's also taken me some time to appreciate my strengths and what I bring to a team and how how I might leverage that in a new opportunity depends on the details. it but it is a it is a tough journey. So if I were to do it again, I would definitely go into it much more eyes wide open and with a focus on who I'm who I'm gonna be in the trenches with and and who I'm going to be helping in the process. speaker-0: Yes. Well, this has just been a tremendous conversation and I'm certainly looking forward to and everyone who's listening is looking forward to watching the next steps in the journey. Congratulations thus far. But at the same time it feels like there's so much more ahead of you and ahead of Zenflow. So all the best with that. speaker-1: Thank you. I appreciate that. And one note on that that I'll just say that I think of in cycling a lot is just because you've reached a peak doesn't mean you've reached the peak. And there's always the next thing to tackle. We have a value at Zenflo that's like celebrate the wins. So, you know, however small when we accomplish something, let's celebrate it. Let's take a moment to appreciate what we've just done. sometimes that's a reminder to myself. I have a a habit of just going on to the next thing. but we gotta pause, we gotta appreciate it, enjoy the moment, and then move on to the next thing and we'll get there. Everything's figured outable, so we'll get there. but it's always it one one foot in front of the other is the best we can do. speaker-0: I love that. I love that. Well I'll see you on the next peak. And and thanks again, Trey, for having me on. This was just an incredible conversation. speaker-1: Thanks Amari. I really appreciate the opportunity to share my story and share share Zenflo's story as well. speaker-0: Absolutely. And thanks to all of you for joining us today on Powering the Future Within. If this conversation inspired you, follow the show and share it with your med tech community. I'm Omari Bachnight. Stay inspired and keep innovating.